Our summary of neurological news items from the European Medicines Agency (EMA) December 2024 Human Medicines Newsletter.
The December 2024 issue of Human Medicines Highlights reflects on a productive year, emphasising the crucial contributions of patient, consumer, and healthcare professional representatives in shaping EMA activities. Key updates include initiatives to address medicine shortages, progress within the ACT EU framework for clinical trials, and a collaborative report on Alzheimer’s disease with the EU-Innovation Network and CNS Working Party.
Medicine Shortages
The EMA underscores the impact of medicine shortages on patient care and healthcare systems. Key measures include strengthening collaboration with stakeholders, enhancing monitoring systems, and ensuring sustainable medicine supply chains. Please click here for more information.
Alzheimer’s Disease
A new report on Alzheimer’s disease, developed in collaboration with the EU-Innovation Network and the Central Nervous System Working Party (CNS), explores the latest advances in research related to diagnosis and treatment strategies. The report highlights the critical role of biomarkers and provides valuable insights into emerging therapeutic approaches for the future. Please click here for more information.
ETF Statement on Monoclonal Antibodies
The EMA Emergency Task Force (ETF) has concluded that authorised monoclonal antibodies for COVID-19 prevention and treatment are unlikely to be effective against newer SARS-CoV-2 variants. The agency emphasises vaccination as the primary preventive measure. Please click here for more information.
ACT EU Updates
The Accelerating Clinical Trials in the EU (ACT EU) initiative is highlighted for its role in fostering a more efficient, collaborative and attractive clinical research environment across Europe. By streamlining processes, fostering innovation, and enhancing accessibility ACT EU benefits patients, healthcare professionals, and researchers alike. Please click here for more information.
